Recent findings have demonstrated how in PCOS patients with high anti-Müllerian hormone (AMH) levels, the letrozole co-administration to GnRH-ant protocols results in a lower OHSS incidence than conventional GnRH-ant protocols. This evidence concerns the gene AMH and ovarian hyperstimulation syndrome.